Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High-Risk CSCC
NCT07100925Phase 1Withdrawn
- Sponsor
- Ankyra Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2030
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, open-label, single-arm trial of tolododekin alfa in cutaneous squamous cell carcinoma (cSCC), sponsored by Ankyra Therapeutics. Primary endpoint: Major Pathological Response rate at 3 months. Planned start Dec 2025; status: withdrawn.
02
Drugs
tolododekin alfa
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT07100925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100925.